The full Johnson & Johnson (JNJ) reaction history

JNJ news moved a median of +0.03% by the close. Every JNJ news event with the realized, point-in-time move the market made — the same measurement, headline by headline. Back to the JNJ overview →

Half of the 469 JNJ news events with a measured close landed between -0.56% and +0.54%; 52% closed up.

By year and event type

JNJ reaction counts across 4 years.

Event type2026202520242023Total
Press release9815212116387
SEC filing · Form 8-K71112636
SEC filing · Form 13F-HR544114
SEC filing · Form 10-Q23319
SEC filing · Form 11-K11204
SEC filing · Form DEFA14A11204
SEC filing · Form 10-K11103
SEC filing · Form ARS11103
SEC filing · Form DEF11103
SEC filing · Form N-PX11103
SEC filing · Form SD11103
SEC filing · Form 8-A12B01102
SEC filing · Form CERT01102
SEC filing · Form S-3ASR10001
All types12017915124474

Counts from the full measured window for JNJ, not just the free rows below — every event type we have labeled, year by year.

Archive pages

Older JNJ news pages.

Page 1 is the JNJ overview; pages 2–10 carry the rest of the measured list.

The 10 most recent JNJ reactions.

DateHeadlineEventSource5-minTo close
New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with MenopausePress releaseBusiness Wire-0.33%—
Spondylitis Association of America Adds Two Distinguished Leaders to Board of DirectorsPress releasePR Web+0.14%—
Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG)Press releasePR Newswire+0.40%-0.57%
Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic arthritis (PsA) studyPress releasePR Newswire+0.05%+0.39%
Single infusion of CARVYKTI® (ciltacabtagene autoleucel) delivered five-year treatment-free remissions in 50% of patients in early line relapsed/refractory multiple myelomaPress releasePR Newswire+0.05%+0.42%
New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term survival expectations in early line relapsed/refractory multiple myelomaPress releasePR Newswire-0.08%-0.68%
DePuy Synthes Showcases Next-Generation Trauma Innovations at OTA 2026Press releaseBusiness Wire-0.28%+0.83%
CAPLYTA® (lumateperone) shows significant and rapid improvement in bipolar mania in pivotal Phase 3 studyPress releasePR Newswire+0.67%-0.06%
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus LAZCLUZE® (lazertinib) with prophylactic strategies shows low rates of treatment-related events at WCLC 2026Press releasePR Newswire-0.99%+0.52%
Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancerPress releasePR Newswire-0.41%-1.73%

464 more JNJ reactions are behind a free account. Create one to see all 474 measured JNJ events — the same point-in-time reactions, every headline.

See all 474 JNJ events →

No credit card · 100 free credits/mo

Keep exploring

More JNJ: earnings → · analyst actions → · SEC filings → · JNJ overview →

Other Health Care names, measured the same way

TickerEventsMedian 30-min% positive
Eli Lilly (LLY)2,000++0.03%52%
UnitedHealth Group (UNH)2,000+-0.03%48%

Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.